Saturn V Capital Management LP

Saturn V Capital Management LP reported 24 holdings worth US$683M as of Sep 30, 2026 (Form 13F)

As of Sep 30, 2026 · Filed Nov 16, 2026

Saturn V Capital Management LP reported 24 holdings worth US$683M as of Sep 30, 2026. Largest: Amylyx Pharmaceuticals, Inc., Abivax SA and Immix Biopharma, Inc. Filed Nov 16, 2026 (Form 13F).

Holdings
24
Value as reported
US$683M

The filing in full

CompanySharesValue as reported% of portfolio
Amylyx Pharmaceuticals, Inc.4.47MUS$130M19.0%
Abivax SA529KUS$52.4M7.7%
Immix Biopharma, Inc.4.66MUS$48.5M7.1%
Vaxcyte, Inc.772KUS$43.9M6.4%
Celcuity Inc.514KUS$40.9M6.0%
Disc Medicine, Inc.613KUS$40.1M5.9%
Candel Therapeutics, Inc.3.48MUS$36.3M5.3%
Monopar Therapeutics Inc.312KUS$24.9M3.6%
Vir Biotechnology, Inc.2.04MUS$22.8M3.3%
Trevi Therapeutics, Inc.1.57MUS$22.5M3.3%
X4 Pharmaceuticals, Inc.7.37MUS$21.4M3.1%
Alumis Inc.2.86MUS$21.1M3.1%
Sagimet Biosciences Inc. - Series A2MUS$19.8M2.9%
Dyne Therapeutics, Inc.837KUS$13.5M2.0%
Alto Neuroscience, Inc.518KUS$13.2M1.9%
Ultragenyx Pharmaceutical Inc.759KUS$11.4M1.7%
Zura Bio Limited2.03MUS$8.46M1.2%
Inhibikase Therapeutics, Inc.3.87MUS$7.95M1.2%
Erasca, Inc.514KUS$7.54M1.1%
Latigo Biotherapeutics, Inc.300KUS$5.02M0.73%
Satellos Bioscience Inc517KUS$4.39M0.64%
Invivyd, Inc.0US$00.00%
Ovid Therapeutics Inc.0US$00.00%

Source

Download original · View original at SEC

Related